Every patient is unique.
Their treatment should be too.
Creating the new standard of care for interventional pulmonary embolism treatment
Why We’re Innovating
900,000 Americans experience a pulmonary embolism annually
Pulmonary embolism (PE) is a major public health problem, causing 100,000 deaths and costing $10 billion in the US every year. 280,000 PEs can be treated with catheter directed thrombolysis (CDT) annually.
PE causes difficulty breathing, heart failure, & death
When a PE occurs, a blood clot obstructs the blood flow in the lungs, causing pressure to build on the heart, which makes it difficult for patients to breathe. The goal of CDT is to dissolve the clot and normalize the pressure.
Imprecise treatment leads to costly complications
Too much lytic may case bleeding complications, but not enough can cause long term pulmonary hypertension. An inability to find just the right time to stop the medication leads to 10.9% 30 day readmission rates and 22.3% 180 day readmission rate for CDT.
Meet the Flow Medical Team
Industry leaders with a passion for improving patient care and advancing medicine through innovative technology solutions.
-
Jonathan Paul, MD
CO-FOUNDER
CHIEF SCIENTIFIC OFFICER
Dr. Paul is an Interventional Cardiologist and Associate Professor of Medicine at the University of Chicago Medical Center.
-
Osman Ahmed, MD
CO-FOUNDER
CHIEF MEDICAL OFFICER
Dr. Ahmed is an Interventional Radiologist and Associate Professor of Radiology at the University of Chicago Medical Center.
-